Impact of Japanese regulatory action on metformin-associated lactic acidosis in type II diabetes patients

Int J Clin Pharm. 2015 Jun;37(3):537-45. doi: 10.1007/s11096-015-0097-0. Epub 2015 Mar 31.

Abstract

Background: The March 2012 regulatory action issued by the Japanese government signalled the rare but serious complication of lactic acidosis that can occur during metformin treatment, especially with the high dose formulation, h-metformin, and in those above 75 years old.

Objective: To assess quantitatively the impact of this regulatory action on patient management using a medical information database (MID).

Setting: Eight hospitals in Japan.

Method: Using a commercial MID, we collected data on adult outpatients treated with metformin, including h-metformin, during a 2-year study period between April 1, 2011 and March 31, 2013. The 2-year study period spanned 1 year before and after the regulatory action. The frequencies of lactate measurement in all metformin users, h-metformin users, and new users (started on metformin during the study period) were compared between the periods before and after the regulatory action, using generalized estimating equations. Trends in metformin prescription for elderly patients were analysed month-wise by regression analysis using an interrupted time series design.

Main outcome measure: The rate ratios (RR) of lactate testing before and after the regulatory action.

Results: Of 4347 metformin users, 784 patients were >75 years old. A significant increase in lactate measurement was observed after the regulatory action than before in the overall study population, with an adjusted RR of 2.14 (95 % confidence interval 1.24-3.68). No significant change was found in h-metformin users and new users because lactate measurements were being performed as frequently in these subgroups before the regulatory action. There were no meaningful changes in the proportion of elderly metformin users in the overall population.

Conclusion: The regulatory action led to increased lactate measurement in the overall metformin users, but did not affect metformin prescription rate in the elderly patients. Our findings probably reflect the doctors' judgement that the benefits of metformin use outweigh the risk of lactic acidosis if lactate testing is performed regularly.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acidosis, Lactic / blood
  • Acidosis, Lactic / chemically induced*
  • Acidosis, Lactic / epidemiology*
  • Adult
  • Aged
  • Cohort Studies
  • Data Collection
  • Databases, Factual
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Drug and Narcotic Control*
  • Female
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / adverse effects
  • Japan / epidemiology
  • Lactic Acid / blood
  • Male
  • Metformin / administration & dosage
  • Metformin / adverse effects*
  • Middle Aged
  • Practice Patterns, Physicians' / statistics & numerical data*
  • Retrospective Studies
  • Young Adult

Substances

  • Hypoglycemic Agents
  • Lactic Acid
  • Metformin